Navigation Links
Xenon Receives a Milestone Payment for Marketing Approval of Glybera in Europe

VANCOUVER, British Columbia, Feb. 5, 2013 /PRNewswire/ -- Xenon, a clinical stage biopharmaceutical company developing novel therapeutics for rare diseases, today announced that it has received a milestone payment from uniQure BV for the European Commission marketing approval of Glybera®, a novel gene therapy treatment for the orphan disease lipoprotein lipase deficiency (LPLD), and the first gene therapy approved in the Western world.

Xenon exclusively licensed to uniQure BV its rights to the LPLS447X genetic variant that causes a gain of function in the lipoprotein lipase (LPL) gene in humans.  Humans with the LPLS447X variant have been shown on average to have lower triglyceride and higher HDL cholesterol levels than those without LPLS447X.  Glybera developed by uniQure is an adeno-associated virus based human gene therapy that contains LPLS447X and in clinical studies Glybera was effective in reducing blood fat levels and episodes of pancreatitis in patients with LPLD.

"The approval of Glybera is an important milestone for our Company and for the gene therapy field in general," said Simon Pimstone , President and CEO of Xenon. "Xenon was founded with a commitment to advancing human genetic discoveries into novel therapies for difficult to treat orphan diseases and Glybera is the first product to be marketed by one of our licensees."

In addition to the milestone payment Xenon is also entitled to receive from uniQure BV royalty payments on sales of Glybera, which is expected to start selling in Europe in 2013. The LPLS447X technology in Glybera was conceived and developed by Xenon's former CSO Michael Hayden at the Center of Molecular Medicine, University of British Columbia.

About Xenon Pharmaceuticals Inc. (Xenon)

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing novel therapies for rare diseases. For more information, visit the Company's website at

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

Xenon Pharmaceuticals Inc., 200- 3650 Gilmore Way, Burnaby, British Columbia, V5G 4W8, Canada,

SOURCE Xenon Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics
2. Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award
3. UF receives $1 million from Keck Foundation to study mechanisms of inherited disease
4. Gladstone scientist Warner C. Greene receives Washington University School of Medicine Alumni Award
5. Carnegies Wolf B. Frommer receives Bogorad Award for Excellence in Plant Biology
6. UC Riverside plant cell biologist receives top scientific honor
7. UC Riverside receives grant for global health and development research
8. Washington University receives $8 million to lead international childhood malnutrition effort
9. SRI Sarnoffs Iris on the Move® N-Glance™ Identification System Receives Lenel Factory Certification
10. SF State biology department receives $1.5 million to support science teaching
11. Dr. Karen Lloyd receives WHOIs Holger W. Jannasch Visiting Scholar Award
Post Your Comments:
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
Breaking Biology News(10 mins):
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... Windsor, Connecticut (PRWEB) , ... June 23, 2016 ... ... will introduce a new line of intelligent tools designed, tuned and optimized exclusively ... place September 12–17 in Chicago. The result of a collaboration among several companies ...
Breaking Biology Technology: